HRA Pharma Report issue

Contributed to NME For profit Phase 2 Phase 3 Phase 4
Founded: Paris France (1996)
Status: Acquired by Perrigo (2021)

Organization Overview

First Clinical Trial
2004
NCT00456924
First Marketed Drug
1996
metyrapone (metopirone)
First NDA Approval
2010
ulipristal (ella)
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

HRA Pharma | HRA PHARMA | LAB HRA PHARMA | LABORATOIRE HRA | LABORATORIE HRA

Active Ingredients

Marketed Drugs (4)

metyrapone (metopirone) (1961 NDA)

mitotane (lysodren) (1970 NDA)

norgestrel (Ovral) (1973)

ulipristal (ella) (2010 NDA)

Drugs in Phase 4 Trials (3)

ethinyl estradiol (Estinyl) (1 trial)

norgestrel (Ovral) (5 trials)

ulipristal (ella) (7 trials)

Drugs in Phase 3 Trials (1)

metyrapone (metopirone) (1 trial)

Drugs in Phase 2 Trials (1)

mifepristone (mifeprex) (1 trial)

Indications

Approved Indications


 

Adrenal Insufficiency

Adrenocortical Carcinoma

Cushing Syndrome

Pregnancy

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cardiac Complexes, Premature (Phase 2)

Cushing Syndrome (Phase 3)

Emergencies (Phase 4)

Genital Diseases, Female (Phase 2)

Leiomyoma (Phase 2)

Myofibroma (Phase 2)

Rupture (Phase 2)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 12
  • # of Trial APIs: 5